AUTOLOGOUS MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

急性淋巴细胞白血病患者的自体骨髓移植

• 批准号: 3817221
• 负责人: KRISTINE DONEY
• 金额: --
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3817221
• 关键词: autologous transplantation; bone marrow transplantation; hematopoietic growth factor; human subject; human therapy evaluation; lymphoblast; lymphocytic leukemia; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer therapy; remission /regression; transforming growth factors

The purpose of this subproject is to evaluate techniques for autologous marrow transplantation (AMI) which will improve the survival of patients with acute lymphoblastic leukemia (ALL) in second marrow remission. Since relapse is the major cause of death following AMI, a conditioning regimen that has been reported successful in decreasing relapse rates in recipients of allogeneic marrow grafts will be evaluated. Patients will receive marrow depleted of either T or B cells depending on lymphoblast phenotyping data. Outcome of autologous transplantation will be compared to that of similar allografted patients to determine relative efficacy. The cohort of patients accrued in this subproject along with those in subprojects I.B., I.C., and I.D. also will be eligible for administration of recombinant hematopoietic growth factors to overcome graft failure or to enhance engraftment (Project VI).

这个分项目的目的是评估技术， 自体骨髓移植（AMI），这将改善 急性淋巴细胞白血病（ALL）患者的生存率 第二次骨髓缓解。 因为复发是死亡的主要原因 据报道，AMI后有一种预处理方案 成功降低同种异体移植受体的复发率 将评估骨髓移植物。 患者将接受骨髓移植 根据淋巴母细胞，T或B细胞耗竭 表型数据。 自体移植的结果将是 与类似的同种异体移植患者相比， 相对功效 这一队列的患者 沿着于次级项目一. B，I. C.，和I.D. 也将有资格给予重组 造血生长因子，以克服移植失败或 加强植入（项目VI）。